Clinical Trial Update: A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM) [Phase 4]

View source ↗

Summary

Phase 4 study of ibrutinib in Chinese participants with relapsed or refractory Waldenström macroglobulinemia has been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• IMBRUVICA (IBRUTINIB)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Waldenstrom Macroglobulinemia | Phase 4 | Status: COMPLETED | Results posted: 2025-04-16